Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts
Link, Brian K. , Ghesquières, Hervé , Nicolas, Émmanuelle , Thompson, Carrie A. , Traverse‐Glehen, Alexandra , Allmer, Cristine, Ansell, Stephen M. , Salles, Gilles , Link, Brian K , Salles, Gilles A , Sarkozy, Clémentine , Maurer, Matthew J. , Nicolas, Emmanuelle, Feldman, Andrew L. , Slager, Susan L. , Habermann, Thomas M. , Bachy, Emmanuel , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | November 27, 2018 | Volume: 37 | Issue: 2 | Pages: 144-152

10.1200/jco.18.00400 | PMID 30481079 Get It

Purpose Although the life expectancy of patients with follicular lymphoma (FL) has increased, little is known of their causes of death (CODs) in the rituximab era. Patients and Methods We pooled two cohorts of newly diagnosed patients with FL grade 1-3A. Patients were enrolled between 2001 and 2013 in two French referral institutions (N = 734; median follow-up 89 months) and 2002 and 2012 in the University of Iowa and Mayo Clinic Specialized Program of Research Excellence (SPORE; N = 920; median follow-up 84 months). COD was classified as being a result of lymphoma, other malignancy, treatment related, or all other causes. Results Ten-year overall survival was comparable in the French (80%) and US (77%) cohorts. We were able to classify COD in 248 (88%) of 283 decedents. In the overall cohort, lymphoma was the most common COD, with a cumulative incidence of 10.3% at 10 years, followed by treatment-related mortality (3.0%), other malignancy (2.9%), other causes (2.2%), and unknown (3.0%). The 10-year cumulative incidence of death as a result of lymphoma or treatment was higher than death as a result of all other causes for each age group (including patients ≥ 70 years of age at diagnosis [25.4% v 16.6%]) Follicular Lymphoma International Prognostic Index score 3 to 5 (27.4% v 5.2%), but not Follicular Lymphoma International Prognostic Index score 0 to 1 (4.0% v 3.7%); for patients who failed to achieve event-free survival within 24 months from diagnosis (36.1% v 7.0%), but not for patients who achieved event-free survival within 24 months of diagnosis (6.7% v 5.7%); and for patients with a history of transformed FL (45.9% v 4.7%), but not among patients without (8.1% v 6.2%). Overall, 77 of 140 deaths as a result of lymphoma occurred in patients whose FL transformed after diagnosis. Conclusion Despite the improvement in overall survival in patients with FL in the rituximab era, their leading COD remains lymphoma, especially after disease transformation. Treatment-related mortality also represents a concern, which supports the need for less-toxic therapies.
Findings of CT-Derived Bone Strength Assessment in Inflammatory Bowel Disease Patients Undergoing CT Enterography in Clinical Practice
Maldonado, Francisco J., Al‐Bawardy, Badr , Nehra, Avinash , Lee, Yong S. , Bruining, David H. , Adkins, Mark C., Keaveny, Tony M. , Johnson, Matthew P. , Fidler, Jeff L. , Al Bawardy, Badr F, Nehra, Avinash K, Maldonado, Francisco J, Fidler, Jeff L. , McCollough, Cynthia H. , Fletcher, Joel G.

Mayo Clinic

Inflammatory Bowel Diseases | November 26, 2018 | Volume: 25 | Issue: 6 | Pages: 1072-1079

10.1093/ibd/izy341 | PMID 30476314 Get It

2029. Comparison of Primers Amplifying Two Different Regions of the 16S Ribosomal RNA Gene for Microbiologic Diagnosis of Cardiovascular Implantable Electronic Device Infection
Garrigos, Zerelda Esquer , Greenwood‐Quaintance, Kerryl E. , Vijayvargiya, Prakhar , Thoendel, Matthew , Friedman, Paul A. , Sohail, M. Rizwan , Patel, Robin

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S591-S591

10.1093/ofid/ofy210.1685 Get It

322. Joint Spacer Retention, Antimicrobial Suppression, and Risk of Re-infection
Valencia, Jose Carlo, Osmon, Douglas R. , Abdel, Matthew P. , Razonable, Raymund R.

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S129-S130

10.1093/ofid/ofy210.333 Get It

Sensor Technology Embedded in Stents: A Potential New Approach to Continuous Monitoring for in Stent Stenosis, Thrombosis, and Beyond
Abi-Aad, Karl R., Welz, Matthew E., Hess, Ryan A. , Bendok, Bernard R. , Hess, Ryan

Mayo Clinic

Neurosurgery | November 23, 2018 | Volume: 84 | Issue: 3 | Pages: E132-E133

10.1093/neuros/nyy616 | PMID 30690481 Get It

MRI Outperforms [18F]AV‐1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy
Whitwell, Jennifer L. , Tosakulwong, Nirubol , Botha, Hugo , Senjem, Matthew L. , Spychalla, Anthony J., Ahlskog, J. Eric , Petersen, Ronald C. , Jack, Clifford R. , Lowe, Val J. , Josephs, Keith A. , Jack, Clifford R , Senjem, Matthew L , Botha, Hugo , Schwarz, Christopher G. , Knopman, David S.

Mayo Clinic

Movement Disorders | November 23, 2018 | Volume: 34 | Issue: 1 | Pages: 105-113

10.1002/mds.27546 | PMID 30468693 Get It

AbstractBackgroundElevated uptake of the [18F]AV‐1451 tau‐PET ligand has been observed cross‐sectionally in subjects with progressive supranuclear palsy (PSP). However, it is unknown how the ligand performs longitudinally in PSP. We aimed to determine how regional measures of change on [18F]AV‐1451 PET perform as longitudinal biomarkers of PSP compared with the more established biomarker of rate of midbrain atrophy.MethodsSixteen subjects with PSP underwent 2 serial [18F]AV‐1451 tau‐PET scans and 3‐Tesla MRI over 12 months and were age‐ and sex‐matched to 39 healthy controls with longitudinal [18F]AV‐1451 PET. Median [18F]AV‐1451 uptake was calculated for each scan for regions of interest across the brain and divided by uptake in cerebellar crus to create standard uptake value ratios. Midbrain volume on MRI was also calculated for each scan. Sample sizes required to power placebo‐controlled treatment trials were calculated.ResultsRate of midbrain atrophy was significantly increased in PSP compared with controls. [18F]AV‐1451 regional change measures were significantly increased in PSP compared with controls in the pallidum, precentral cortex, dentate nucleus of the cerebellum, and midbrain. Change over time in the PSP Rating Scale correlated with change in midbrain volume but did not correlate with change in the [18F]AV‐1451 measures. Smallest sample‐size estimates were obtained with rate of midbrain atrophy, followed by the PSP Rating Scale, with both outperforming [18F]AV‐1451 measures.Conclusions[18F]AV‐1451 tau‐PET measures increase over time in subjects with PSP, but longitudinal [18F]AV‐1451 measures may not perform as well as rate of midbrain atrophy as biomarkers for PSP clinical trials. © 2018 International Parkinson and Movement Disorder Society
A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR
Gunter, Jeffrey L. , Lowe, Val J. , Weigand, Stephen D. , Vemuri, Prashanthi , Senjem, Matthew L. , Petersen, Ronald C. , Jack, Clifford R. , Jack, Clifford R , Vemuri, Prashanthi , Senjem, Matthew L , Schwarz, Christopher G. , Knopman, David S.

Mayo Clinic

Journal of Alzheimer's Disease | November 23, 2018 | Volume: 67 | Issue: 1 | Pages: 181-195

10.3233/jad-180749 | PMID 30475770 Get It

Effect of Modified Japanese Orthopedic Association Severity Classifications on Satisfaction With Outcomes 12 Months After Elective Surgery for Cervical Spine Myelopathy
Asher, Anthony L. , Devin, Clinton J. , Weisenthal, Benjamin M., Pennings, Jacquelyn S. , Khan, Inamullah , Archer, Kristin R. , Sivaganesan, Ahilan, Chotai, Silky , Bydon, Mohamad , Nian, Hui , McGirt, Matthew J., Mummaneni, Praveen V. , Bisson, Erica F. , Shaffrey, Christopher I. , Foley, Kevin T. , Harrell, Frank E.

Mayo Clinic

Spine | November 21, 2018 | Volume: 44 | Issue: 11 | Pages: 801-808

10.1097/brs.0000000000002946 | PMID 30475334 Get It

Study Design. This study retrospectively analyzes prospectively collected data. Objective. Here, we aim to determine the influence of preoperative and 12-month modified Japanese Orthopedic Association (mJOA) on satisfaction and understand the change in mJOA severity classification after surgical management of degenerative cervical myelopathy (DCM). Summary of Background Data. DCM is a progressive degenerative spine disease resulting from cervical cord compression. The natural progression of DCM is variable; some patients experience periods of stability, while others rapidly deteriorate following disease onset. The mJOA is commonly used to grade and categorize myelopathy symptoms, but its association with postoperative satisfaction has not been previously explored. Methods. The quality and outcomes database (QOD) was queried for patients undergoing elective surgery for DCM. Patients were divided into mild (≥14), moderate (9 to 13), or severe (<9) categories on the mJOA scores. A McNemar–Bowker test was used to assess whether a significant proportion of patients changed mJOA category between preoperative and 12 months postoperative. A multivariable proportional odds ordinal logistic regression model was fitted with 12-month satisfaction as the outcome of interest. Results. We identified 1963 patients who underwent elective surgery for DCM and completed 12-months follow-ups. Comparing mJOA severity level preoperatively and at 12 months revealed that 55% remained in the same category, 37% improved, and 7% moved to a worse category. After adjusting for baseline and surgery-specific variables, the 12-month mJOA category had the highest impact on patient satisfaction (P < 0.001). Conclusion. Patient satisfaction is an indispensable tool for measuring quality of care after spine surgery. In this sample, 12-month mJOA category, regardless of preop mJOA, was significantly correlated with satisfaction. Given these findings, it is important to advise patients of the probability that surgery will change their mJOA severity classification and the changes required to achieve postoperative satisfaction. Level of Evidence: 3
Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion
McKernin, Shannon, Moravek, Cassadie, Nagarajan, Arun , Petersen, Gloria M. , Simeone, Diane M. , Yurgelun, Matthew B. , Khorana, Alok A. , Stoffel, Elena M. , Brand, Randall E. , Canto, Marcia Irene , Goggins, Michael

Mayo Clinic

Journal of Clinical Oncology | November 20, 2018 | Volume: 37 | Issue: 2 | Pages: 153-164

10.1200/jco.18.01489 | PMID 30457921 Get It

Purpose An ASCO provisional clinical opinion (PCO) offers timely clinical direction to ASCO’s membership and other health care providers. This PCO addresses identification and management of patients and family members with possible predisposition to pancreatic adenocarcinoma. Methods ASCO convened an Expert Panel and conducted a systematic review of the literature published from January 1998 to June 2018. Results of the databases searched were supplemented with hand searching of the bibliographies of systematic reviews and selected seminal articles and contributions from Expert Panel members’ curated files. Provisional Clinical Opinion All patients diagnosed with pancreatic adenocarcinoma should undergo assessment of risk for hereditary syndromes known to be associated with an increased risk for pancreatic adenocarcinoma. Assessment of risk should include a comprehensive review of family history of cancer. Individuals with a family history of pancreatic cancer affecting two first-degree relatives meet criteria for familial pancreatic cancer (FPC). Individuals (cancer affected or unaffected) with a family history of pancreatic cancer meeting criteria for FPC, those with three or more diagnoses of pancreatic cancer in same side of the family, and individuals meeting criteria for other genetic syndromes associated with increased risk for pancreatic cancer have an increased risk for pancreatic cancer and are candidates for genetic testing. Germline genetic testing for cancer susceptibility may be discussed with individuals diagnosed with pancreatic cancer, even if family history is unremarkable. Benefits and limitations of pancreatic cancer screening should be discussed with individuals whose family history meets criteria for FPC and/or genetic susceptibility to pancreatic cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .